Bioniq, which is renowned for its personalized nutritional supplements based on blood biomarker data, has signed up football star Diogo Dalot, right-back for Manchester United and the Portugal national team, as an investor, contributing over €1 million.

Dalot joins the global football icon Cristiano Ronaldo, who became a major investor in 2024, and brought Bioniq's total valuation to $82 million. Dalot's investment marks another milestone in Bioniq's mission to make personalized health accessible to athletes and everyday individuals worldwide.

UK agritech startup Elaniti has closed its recent funding round with participation from early-stage biotech investor biotope by VIB, Planetary Impact Ventures and Paulig Group's CVC arm, PINC.

Healsgood, the pioneering healthtech company behind Flexzo AI, has successfully closed a £1.5 million funding round to revolutionise staffing and operational efficiency across the NHS. The oversubscribed round, led by Fuel Ventures, signifies strong investor confidence in Healsgood's vision of dramatically reducing patient waiting times and NHS service delivery failures across the UK.

Eventum Orthopaedics, a UK medtech company whose device could revolutionise knee replacement surgery has raised a further £3.8m from NPIF II - Mercia Equity Finance, which is managed by Mercia Ventures as part of the Northern Powerhouse Investment Fund II (NPIF II), Mercia’s EIS funds and private investors including leading surgeons.

Eventum's QuadSense device helps surgeons to precisely cut and place the kneecap in total knee replacements. Currently over 2 million patients a year have knee replacements globally, yet around 20% are not fully satisfied with the outcome. Eventum believes the key to improving success rates is the position of the kneecap, which plays a crucial role in the knee's function.

Reactwise has secured $3.4 million in pre-seed funding, including a competitive Innovate UK grant, to enable AI-driven robotic laboratories and speed up pharmaceutical manufacturing R&D. 

Edinburgh-based biotech company Lentitek Ltd has secured £700,000 in private funding from Equity Gap, a leading Scottish angel investment syndicate, bringing its total investment to £1 million in the last six months. This follows a £300,000 Innovate UK grant awarded recently, earlier, accelerating the development and commercialisation of its groundbreaking viral vector technology for next-generation cancer treatments.

Health and Care Innovations (HCI) has secured a £375,000 equity investment from the British Business Bank's South West Investment Fund via appointed Fund Manager, The FSE Group, as well as from new and existing angel investors.

StimOxyGen, a spin-out from Ulster University, has raised £1.5m, led by DSW Ventures, to accelerate the development of its innovative therapy designed to overcome treatment resistance in solid tumours.

Lant Medical has secured £500,000 investment from Innovate UK, the UK's innovation agency, and two angel investors from the Northern Investor Hub to design a clinical trial for a promising new non-antibiotic treatment, designed to eradicate cancer-causing Helicobacter pylori (H. pylori).

Approxima closed the first part of a Series A financing round securing €7.3M. The round was co-lead by ENEA Tech e Biomedical and Panakès Partners with strong continued support from current shareholders Club degli Investitori through Simon Fiduciaria and other business angels. 

Prorizon, a Manchester-based health and sports tech start up, has raised £400k in a pre-seed funding round, with GC Angels leading the investment in partnership with Innovate UK. The funding was secured alongside an Innovate UK Investor Partnership award with the Department for Digital, Culture, Media, and Sport (DCMS), as well as additional backing from angel investors.

The investment will accelerate Prorizon's platform development, integrating advanced AI technology to provide personalised and preventative interventions for individuals managing both physical and psychological stress. 

Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used to fund its schizophrenia programme and drive the next stage of growth for the company.